Quarterly report pursuant to Section 13 or 15(d)

Supplemental Equity and Accumulated Other Comprehensive Income (Loss) - Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax (Details)

v3.22.4
Supplemental Equity and Accumulated Other Comprehensive Income (Loss) - Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax (Details) - USD ($)
$ in Thousands
 6 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Balance $ 1,701,770  
Balance 1,827,106  
AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]    
Balance 8,069 $ (6,193)
Other comprehensive income (loss) before reclassifications, net of taxes, attributable to Bio-Techne 4,484 1,682
Reclassification from (gain) loss on derivatives to interest expense, net of taxes, attributable to Bio-Techne(1) (474) 2,884
Balance 12,079 (1,626)
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]    
Balance (83,269) (51,098)
Other comprehensive income (loss) before reclassifications, net of taxes, attributable to Bio-Techne (4,087) (6,750)
Reclassification from (gain) loss on derivatives to interest expense, net of taxes, attributable to Bio-Techne(1)   0
Reclassification of cumulative translation adjustment for Eminence to non-operating income, net of taxes, attributable to Bio-Techne 152  
Balance (87,204) (57,848)
AOCI Attributable to Parent [Member]    
Balance (75,200) (57,291)
Other comprehensive income (loss) before reclassifications, net of taxes, attributable to Bio-Techne 397 (5,068)
Reclassification from (gain) loss on derivatives to interest expense, net of taxes, attributable to Bio-Techne(1) (474) 2,884
Reclassification of cumulative translation adjustment for Eminence to non-operating income, net of taxes, attributable to Bio-Techne 152  
Balance $ (75,125) $ (59,474)